本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 潘讴东先生为公司实际控制人，截至本公告披露日，潘讴东先生直接持有公司122,805,540股股份，占公 司总股本的18.92%。潘讴东先生辞任总经理后继续担任董事长等职务，将继续遵守法律、法规和规范 性文件的相关规定及所作出的相关承诺。 潘讴东先生在担任公司总经理期间勤勉尽责、恪尽职守，公司及董事会对潘讴东先生在担任公司总经理 期间为公司经营发展做出的贡献表示衷心感谢！ ●和元生物技术（上海）股份有限公司（以下简称"公司"）董事会于近日收到总经理潘讴东先生辞去总 经理职务的书面辞呈。潘讴东先生因计划更专注于履行董事长职责，集中精力统筹公司长期战略规划与 发展方向，进一步优化公司治理结构、提升决策效率，申请不再兼任公司总经理职务。辞任后，潘讴东 先生将继续担任第四届董事会董事长、第四届董事会战略与ESG委员会主任委员、第四届董事会薪酬与 考核委员会委员、第四届董事会提名委员会委员。 ●公司于2025年12月29日召开第四届董事会第五次会议，审议通过了《关于变更公司总 ...

每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ （记者 王瀚黎） 每经AI快讯，和元生物12月30日晚间发布公告称，潘讴东先生因计划更专注于履行董事长职责，集中 精力统筹公司长期战略规划与发展方向，进一步优化公司治理结构、提升决策效率，申请不再兼任公司 总经理职务。潘讴东先生对辞去总经理职务已做好工作安排。潘讴东先生辞任总经理后继续担任董事长 等职务。董事会同意聘任潘俊屹先生为公司总经理。 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-065 和元生物技术（上海）股份有限公司 关于公司总经理变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●和元生物技术（上海）股份有限公司（以下简称"公司"）董事会于近日 收到总经理潘讴东先生辞去总经理职务的书面辞呈。潘讴东先生因计划更专注于 履行董事长职责，集中精力统筹公司长期战略规划与发展方向，进一步优化公司 治理结构、提升决策效率，申请不再兼任公司总经理职务。辞任后，潘讴东先生 将继续担任第四届董事会董事长、第四届董事会战略与 ESG 委员会主任委员、第 四届董事会薪酬与考核委员会委员、第四届董事会提名委员会委员。 ●公司于 2025 年 12 月 29 日召开第四届董事会第五次会议，审议通过了《关 于变更公司总经理的议案》，董事会同意聘任潘俊屹先生为公司总经理，任期自 本次董事会审议通过之日起至公司第四届董事会任期届满之日止。 现将有关情况公告如下： | 姓名 | 离任职 | 离任时间 | 原定任 期到期 | 离任原因 | 是否 ...

Group 1 - The company focuses on cell and gene therapy CRO/CDMO business [2] - The company is actively expanding its overseas business, including the EU market [2] - The company has already secured a small number of CRO service orders for export to EU countries [2]

Group 1 - The company focuses on cell and gene therapy CRO/CDMO business [1] - The company is actively expanding its overseas business, including the EU market [1] - The company has already secured a small number of CRO service orders for export to EU countries [1]

Core Insights - The article discusses the recent financial performance of a major company, highlighting significant revenue growth and strategic initiatives aimed at expanding market share [1] Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $5 billion in the last quarter [1] - Net income rose to $1 billion, reflecting a 20% increase compared to the previous year [1] Strategic Initiatives - The company has launched a new product line expected to contribute an additional $500 million in revenue over the next fiscal year [1] - A strategic partnership with another industry leader is anticipated to enhance distribution channels and improve market penetration [1] Market Trends - The overall industry is experiencing a shift towards digital solutions, with a projected growth rate of 10% annually [1] - Increased consumer demand for sustainable products is influencing company strategies and product development [1]

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry by leveraging strong technological capabilities and strategic focus, aiming to enhance its competitiveness and market penetration in the regenerative medicine sector [1][10]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1][2]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in the transition of China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company has made significant investments in R&D, with R&D expenses reaching 34.66 million yuan in the first three quarters of 2025, accounting for 19.22% of its revenue [3]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2][3]. - The integration of AI technology into drug development processes has been a focus, with the establishment of an intelligent R&D system that enhances efficiency [4]. Group 3: Market Position and Client Base - He Yuan Bio has built a robust client base, collaborating with over 14,700 research laboratories and managing more than 600 CDMO projects, including five Phase III clinical projects [5]. - The company emphasizes the importance of deep technical insights and precise control over process details as core values in its CRO and CDMO services [5]. Group 4: Future Development and Expansion - The company is expanding into the regenerative medicine sector by establishing a wholly-owned subsidiary, He Yuan He Mei, to address challenges in cell safety and traceability [8]. - The company’s production base in Lingang has commenced operations, featuring 11 GMP vector production lines and 18 GMP cell production lines, positioning it among the top in the international industry [6]. - He Yuan Bio aims to enhance its international presence by supporting domestic clients in obtaining overseas IND approvals and facilitating the licensing of proprietary technologies [9]. Group 5: Commitment to Health and Innovation - The company is committed to empowering cell and gene therapy to improve public health, focusing on innovation and collaboration to drive high-quality development in the CGT field [10].

Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry, leveraging strong technological capabilities and strategic focus to navigate industry cycles and achieve significant growth [1][2]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in advancing China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company emphasizes continuous technological innovation, with a focus on core technical capabilities, GMP platform strength, and project management [2]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2]. - R&D expenses for the first three quarters of 2025 reached 34.66 million yuan, accounting for 19.22% of revenue, indicating a strong commitment to innovation [3]. Group 3: AI Integration - The company is actively exploring AI applications in drug development, creating an intelligent R&D system that integrates AI with biological technology [4]. - This dual-driven model of "algorithm innovation + application landing" aims to enhance R&D and production efficiency [4]. Group 4: Market Position and Client Base - He Yuan Bio has built a robust client base, with over 14,700 collaborative research laboratories and more than 600 CDMO projects, including 60 clinical trial approvals [5]. - The company provides a "one-stop" service from laboratory research to commercial production, focusing on technical insight and compliance [5]. Group 5: Future Development and Capacity Expansion - The company is positioned to capitalize on the transition of CGT drug commercialization from "technical breakthroughs" to "scale implementation," supported by technological advancements and policy backing [6]. - The company's Lingang industrial base has commenced full production, featuring 11 GMP vector production lines and 18 GMP cell production lines, placing it among the top in the international industry [6]. - Future capacity utilization at the Lingang base is expected to enhance market share and profitability, supporting growth in the cell and gene therapy sector [6]. Group 6: Expansion into Regenerative Medicine - He Yuan Bio is expanding into regenerative medicine by establishing a wholly-owned subsidiary, He Yuan He Mei, to address industry challenges related to cell safety and traceability [8]. - The company is developing processes for stem cells, immune cells, and exosomes, and is forming strategic partnerships to explore business development paths [8]. Group 7: Internationalization Efforts - The company is pursuing international expansion, aiming to position Chinese cell and gene therapy services on a global scale [8][9]. - He Yuan Bio has achieved a milestone with its Human Fibroblast Extracellular Vesicles being included in the global cosmetics ingredient directory, marking a significant step in its internationalization efforts [9]. Group 8: Commitment to Health and Innovation - He Yuan Bio is dedicated to empowering cell and gene therapy to enhance public health, driven by innovation and collaboration [10].

和元生物临港产业基地 公司供图 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) | 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-16 | 和辉光电 | 688238 | 2.62 | 1637.5 | 625 | 机构专用 | 国泰海通证券股份 | | | 2025-12-16 | 和辉光电 | 688238 | 2.62 | 1637.5 | 625 | 为营证套整合氢限 250 | 国泰海通证券股份 | | 12月16日，和辉光电大宗交易成交1250万股，成交额3275万元，占当日总成交额的19.7%，成交价2.62元，较市场收盘价2.64元折价0.76%。 ...